Industry Symposium 5

There has been a recent change in the standard of care in the management of advanced Urothelial cancers (aUC) with the inclusion of Enfortumab Pembrolizumab & Nivolumab Chemotherapy combination approvals. However,  the experience with the use of these novel agents may be quite limited in Asia Pacific, especially with ADCs. There is therefore a need for education from Experts with expertise in the use of these agents. This symposium is designed with the objective of sharing with clinicians involved in the management of aUC on the latest trends in these disease space.